- Home
- NXL vs CLGN Comparison
NXL vs CLGN Comparison
Compare NXL & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXL
- CLGN
- Stock Information
- Founded
- NXL 2010
- CLGN 2004
- Country
- NXL United States
- CLGN Israel
- Employees
- NXL N/A
- CLGN N/A
- Industry
- NXL Medical Specialities
- CLGN Industrial Specialties
- Sector
- NXL Health Care
- CLGN Health Care
- Exchange
- NXL Nasdaq
- CLGN Nasdaq
- Market Cap
- NXL 21.0M
- CLGN 20.4M
- IPO Year
- NXL 2022
- CLGN N/A
- Fundamental
- Price
- NXL $1.04
- CLGN $1.48
- Analyst Decision
- NXL Strong Buy
- CLGN Strong Buy
- Analyst Count
- NXL 1
- CLGN 2
- Target Price
- NXL $5.00
- CLGN $11.50
- AVG Volume (30 Days)
- NXL 81.9K
- CLGN 272.0K
- Earning Date
- NXL 08-07-2025
- CLGN 08-19-2025
- Dividend Yield
- NXL N/A
- CLGN N/A
- EPS Growth
- NXL N/A
- CLGN N/A
- EPS
- NXL N/A
- CLGN N/A
- Revenue
- NXL $131,065.00
- CLGN $2,472,000.00
- Revenue This Year
- NXL $79.59
- CLGN $2,177.67
- Revenue Next Year
- NXL $334.65
- CLGN $56.52
- P/E Ratio
- NXL N/A
- CLGN N/A
- Revenue Growth
- NXL N/A
- CLGN N/A
- 52 Week Low
- NXL $0.59
- CLGN $1.40
- 52 Week High
- NXL $4.49
- CLGN $5.48
- Technical
- Relative Strength Index (RSI)
- NXL 29.65
- CLGN 41.46
- Support Level
- NXL $1.12
- CLGN $1.40
- Resistance Level
- NXL $1.30
- CLGN $1.83
- Average True Range (ATR)
- NXL 0.09
- CLGN 0.26
- MACD
- NXL 0.00
- CLGN -0.08
- Stochastic Oscillator
- NXL 0.00
- CLGN 4.11
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.